title: Regulatory T cells in Behçet's disease: is there a correlation with disease activity? Does regulatory T cell type matter?
abstract: The aim of this study was to investigate the percentage of regulatory T cells and the correlation with clinical activity in Behçet's disease. Forty Behçet's disease (BD) patients, 18 males and 22 females, were included in the study. The patients were diagnosed according to the published BD criteria. Twenty age- and sex-matched volunteer healthy donors were also included. At the time of sampling, clinical activity was assessed for activity signs and symptoms according to the BD Current Activity Form. We considered active those patients with a clinical activity index equal to and/or above 2. Eleven patients had active disease and the remaining were considered as clinically inactive. We have studied the percentages of CD4+CD25+FOXP3+, CD4+CD25+ and CD4+FOXP3+regulatory T cells by flow cytometry and investigated the correlation with disease activity. Percentage of CD4+CD25+FOXP3+Treg in active patients was lower than clinically inactive patients and healthy controls. Percentage of CD4+CD25+Treg was not different between active and inactive patients and healthy controls. Percentage of CD4+FOXP3+Treg was lower than healthy controls in clinically active patients but was not different for inactive group and healthy controls. Patients were active when CD4+CD25+FOXP3+Treg was ≤1.19 %, CD4+CD25+Treg was ≤2.68 %, and CD4+FOXP3+Treg was ≤2.60. CD4+CD25+FOXP3+Treg and CD4+FOXP3+Treg were found negatively correlated with disease activity. Peripheral blood regulatory T cells are decreased in clinically active Behçet's disease patients. The advances in our understanding of the interactions between distinct subsets of Treg and clinical activity might help in modulating BD treatment.
authors.affiliation: Department of Hematology, School of Medicine, Eskişehir Osmangazi University, Eskisehir, 26480, Turkey, erengunduz@hotmail.com.
authors.forename: Eren
authors.initials: E
authors.lastname: Gündüz
authors.forename: Hava Usküdar
authors.initials: HU
authors.lastname: Teke
authors.forename: Nazife Sule Yaşar
authors.initials: NS
authors.lastname: Bilge
authors.forename: Döndü Usküdar
authors.initials: DU
authors.lastname: Cansu
authors.forename: Cengiz
authors.initials: C
authors.lastname: Bal
authors.forename: Cengiz
authors.initials: C
authors.lastname: Korkmaz
authors.forename: Zafer
authors.initials: Z
authors.lastname: Gülbaş
mesh_terms: D000328:Adult; D001528:Behcet Syndrome / Q000276:immunology / Q000473:pathology / Q000503:physiopathology*; D015704:CD4 Antigens / Q000378:metabolism; D016022:Case-Control Studies; D002452:Cell Count; D005260:Female; D005434:Flow Cytometry; D051858:Forkhead Transcription Factors / Q000378:metabolism; D006801:Humans; D053645:Interleukin-2 Receptor alpha Subunit / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D012720:Severity of Illness Index; D050378:T-Lymphocytes, Regulatory / Q000145:classification / Q000276:immunology* / Q000473:pathology*
chemical_list: D015704:CD4 Antigens; C418974:FOXP3 protein, human; D051858:Forkhead Transcription Factors; D053645:Interleukin-2 Receptor alpha Subunit
references.citation: J Dermatol Sci. 1997 May;15(1):9-13
references.pmid: 9186807
references.citation: Nat Rev Immunol. 2005 Apr;5(4):343-9
references.pmid: 15775994
references.citation: J Exp Med. 2004 Jun 7;199(11):1455-65
references.pmid: 15184499
references.citation: J Neuroimmunol. 2011 Apr;233(1-2):249-53
references.pmid: 21367463
references.citation: Semin Immunol. 2011 Aug;23(4):304-13
references.pmid: 21620722
references.citation: Clin Exp Rheumatol. 2007 Jul-Aug;25(4 Suppl 45):S107-13
references.pmid: 17949563
references.citation: Nat Immunol. 2003 Apr;4(4):330-6
references.pmid: 12612578
references.citation: N Engl J Med. 1999 Oct 21;341(17):1284-91
references.pmid: 10528040
references.citation: Autoimmun Rev. 2012 Aug;11(10):687-98
references.pmid: 22197900
references.citation: Cytotherapy. 2011 Aug;13(7):835-47
references.pmid: 21506890
references.citation: J Oral Pathol Med. 2012 Jan;41(1):73-9
references.pmid: 21736625
references.citation: Lancet. 1990 May 5;335(8697):1078-80
references.pmid: 1970380
references.citation: Rheumatology (Oxford). 1999 Aug;38(8):728-33
references.pmid: 10501420
references.citation: Invest Ophthalmol Vis Sci. 2011 Jan 21;52(1):476-84
references.pmid: 20861484
references.citation: Immunol Rev. 2001 Aug;182:122-34
references.pmid: 11722629
references.citation: PLoS Med. 2006 Aug;3(8):e297
references.pmid: 16942393
references.citation: Clin Exp Rheumatol. 2006 Sep-Oct;24(5 Suppl 42):S71-8
references.pmid: 17067431
references.citation: Mod Rheumatol. 2008;18(4):354-8
references.pmid: 18427720
references.citation: Int Immunol. 2007 Apr;19(4):345-54
references.pmid: 17329235
references.citation: J Allergy Clin Immunol. 2011 Sep;128(3):655-64
references.pmid: 21724243
references.citation: Zhonghua Yan Ke Za Zhi. 2011 May;47(5):393-7
references.pmid: 21756739
references.citation: J Exp Med. 2008 Sep 1;205(9):1975-81
references.pmid: 18710931